Novel controlled-release Lemna-derived IFN-α2b (Locteron):: Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

被引:52
作者
De Leede, Leo G. J. [1 ]
Humphries, John E. [2 ]
Bechet, Anne C. [1 ]
Van Hoogdalem, Ewoud J. [1 ]
Verrijk, Ruud [1 ]
Spencer, David G. [2 ]
机构
[1] OctoPlus NV, Leiden, Netherlands
[2] Bioflex Therapeut, Pittsboro, NC 27312 USA
关键词
D O I
10.1089/jir.2007.0073
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Locteron (TM), a newly developed controlled-release formulation of Lemna-derived free (unpegylated) recombinant interferon-alpha 2b (IFN-alpha 2b, Biolex Therapeutics, Pittsboro, NC) in poly(ether-ester) microspheres (Poly-Active, OctoPlus N.V., Leiden, the Netherlands), was evaluated in 27 volunteers injected with either 20, 80, or 320 mu g Locteron (equivalent to 6.25, 25, or 100 X 10(6) IU, respectively), 80 mu g pegylated IFN-alpha 2b (PEG-IFN-alpha 2b), microspheres not containing IFN-alpha 2b, or placebo. Serum free or PEG-IFN-alpha 2b and two biomarkers of IFN activity, neopterin and 2',5'-oligoadenylate synthetase (2',5'-OAS), were measured. After injection of 320 mu g Locteron, serum IFN-alpha 2b remained elevated through 14 days. The elimination half-life of Locteron was more than 2-fold that of PEG-IFN-alpha 2b. The effects of 80 mu g Locteron and 80 mu g PEG-IFN-alpha 2b on both neopterin and 2',5'-OAS were in a comparable range. Serum persistence of both these biomarkers was similar at 14 days after 320 mu g Locteron compared with 7 days after 80 mu g PEG-IFN-alpha 2b. Mild, moderate, or severe influenza-like symptoms developed in all 6 subjects receiving 80 1Ag PEG-IFN-alpha 2b. No such symptoms occurred after 20 or 80 mu g Locteron doses. Among the 4 recipients of 320 mu g Locteron, 1 experienced mild and 2 experienced moderate influenza-like symptoms. Locteron merits further clinical investigation as a hepatitis C therapy suitable for dosing once per 2 weeks.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 31 条
[1]   Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy [J].
Bagheri, H ;
Fouladi, A ;
Barange, K ;
Lapeyre-Mestre, M ;
Payen, JL ;
Montastruc, JL ;
Vinel, JP .
PHARMACOTHERAPY, 2004, 24 (11) :1546-1553
[2]   A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients [J].
Bain, VG ;
Kaita, KD ;
Yoshida, EM ;
Swain, MG ;
Heathcote, EJ ;
Neumann, AU ;
Fiscella, M ;
Yu, R ;
Osborn, BL ;
Cronin, PW ;
Freimuth, WW ;
McHutchison, JG ;
Subramanian, GM .
JOURNAL OF HEPATOLOGY, 2006, 44 (04) :671-678
[3]   PHARMACOKINETICS OF AN EXTENDED-RELEASE HUMAN INTERFERON-ALPHA-2B FORMULATION [J].
BONETTI, A ;
KIM, S .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (03) :258-261
[4]  
Bruno R, 2005, ANTIVIR THER, V10, P201
[5]   Pharmacokinetics of pegylated interferons: What is misleading? [J].
Caliceti, P .
DIGESTIVE AND LIVER DISEASE, 2004, 36 :S334-S339
[6]   Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1 [J].
Formann, E ;
Jessner, W ;
Bennett, L ;
Ferenci, P .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) :271-276
[7]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[8]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244
[9]  
Gasdaska JR, 2003, BIOPROC J MAR, P50
[10]   Pegylated interferon-α2b:: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [J].
Glue, P ;
Fang, JWS ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :556-567